Cyp1a1 ab235185

Cell pellets corresponded to untreated cells in media, 0.1% DMSO, B[a]P treated (1 μM), DATS treated (40 μM), and CoTx (1 μM B[a]P combined with 40 μM DATS) after 24 h treatment. 0.5% TritonX-100 was mixed with a protease inhibitor cocktail and combined with each pellet. The Pierce BCA Protein Assay kit was used to determine protein concentration. Each sample contained 50 μg of protein. 1:1000 dilution of primary antibody and secondary antibody were used. After the secondary antibody was incubated, the protein was identified, and the digital immunoblot was taken. The primary antibodies tested were CYP1A1 (ab235185) purchased from Abcam (Boston, MA, USA), Hypoxia Pathway Antibody Sampler Kit (#15792), AhR mAb (#83200), and loading control GAPDH mAb (#D16H11) purchased from Cell Signaling (Danvers, MA, USA).

The cell pellets were obtained from untreated cells in media alone, 0.1% DMSO vehicle control, B[a]P (1 μM), DATS (40 μM), and CoTx (1 μM B[a]P combined with 40 μM DATS), respectively, following a 24 h treatment. A mixture of 0.5% TritonX-100 and a protease inhibitor cocktail was added to each pellet, and the Pierce BCA Protein Assay kit was used to determine the protein concentration. Each sample possessed 50 μg of protein, and the primary and secondary antibodies were used at a dilution of 1:1000. Following the incubation with the secondary antibody, the protein was identified, and a digital immunoblot was captured. The primary antibodies assessed included CYP1A1 (ab235185) obtained from Abcam, the Hypoxia Pathway Antibody Sampler Kit (#15792), AhR mAb (#83200), and loading control GAPDH mAb (#D16H11) or Vinculin mAb (#13901) purchased from Cell Signaling.